Paclitaxel Protein-bound Particles For Injectable Suspension (albumin-bound) Injection, Powder, Lyophilized, For Suspension
Product Images NDC 68001-651

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Paclitaxel Protein-bound Particles For Injectable Suspension (albumin-bound) (NDC 68001-651). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Paclitaxel Vial Container Label (Paclitaxel Protein Bound Particles For Inj Susp Vial Rev 0325)

Label for Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 100 mg per vial. This sterile, lyophilized powder injection is for intravenous use only, single-dose vial with discard instructions for unused portions. Labeler is BluePoint Laboratories. The label includes storage instructions, reconstitution details, warnings about functional differences from other paclitaxel products, and product origin information from China.*

FDA Label Image

Paclitaxel Carton Label (Untitled)

Packaging label for Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) 100 mg per vial by BluePoint Laboratories. The label describes the product as a lyophilized powder for injection, with instructions to reconstitute with 20 mL of 0.9% Sodium Chloride Injection. It includes storage instructions, warnings not to substitute with other paclitaxel products, and a barcode. The label notes it is for single-dose vial intravenous use only and specifies the manufacturer, Ningbo Shuangcheng Pharmaceutical Co., Ltd., China.*

FDA Label Image

Figure 1 (Paclitaxel Figure 1)

A survival curve graph showing the proportion of survival over time in months, comparing Paclitaxel protein-bound particles for injectable suspension (albumin-bound) combined with Gemcitabine versus Gemcitabine alone. The vertical axis represents the proportion of survival from 0 to 1, and the horizontal axis represents time up to 39 months. The graph includes the number of patients at risk over time for each treatment group.*

FDA Label Image

Preparation Vial (Paclitaxel Prep Vial)

An instructional line drawing showing a vial of powder labeled for injection being suspended upside down, connected to an intravenous set. A fluid is shown entering the vial from above, indicating the reconstitution or preparation of the intravenous injectable suspension.*

FDA Label Image

Structural Formula For Paclitaxel (Paclitaxel Structure)

Chemical structure diagram of paclitaxel, the active ingredient in Paclitaxel protein-bound particles for injectable suspension (albumin-bound). The diagram shows the molecular arrangement and functional groups of paclitaxel.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.